Compare AGNC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGNC | LEGN |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 5.9B |
| IPO Year | 2008 | 2020 |
| Metric | AGNC | LEGN |
|---|---|---|
| Price | $10.00 | $17.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $11.03 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 19.0M | 1.7M |
| Earning Date | 04-20-2026 | 05-12-2026 |
| Dividend Yield | ★ 13.13% | N/A |
| EPS Growth | ★ 58.06 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.33 | $42.68 |
| Revenue Next Year | $1.16 | $30.52 |
| P/E Ratio | $26.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.63 | $16.24 |
| 52 Week High | $12.19 | $37.50 |
| Indicator | AGNC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 24.94 | 31.42 |
| Support Level | $9.63 | $16.47 |
| Resistance Level | $10.64 | $21.99 |
| Average True Range (ATR) | 0.18 | 0.88 |
| MACD | -0.09 | -0.24 |
| Stochastic Oscillator | 2.83 | 3.31 |
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.